Middleton, Gary
Greenhalf, William
Costello, Eithne
Shaw, Victoria
Cox, Trevor
Ghaneh, Paula
Palmer, Daniel H
Neoptolemos, John P
Article History
Received: 5 October 2015
Revised: 20 November 2015
Accepted: 9 December 2015
First Online: 4 February 2016
Competing interests
: Professor Gary Middleton is funded by CR-UK and has received grants from Astra Zeneca, Merck Sharp Dhome, Novartis and KAEL Gemvax. Professor JP Neoptolemos reports none other than grants from Roche, Cancer Research UK, NIHR, Pancreas Cancer UK, North West Cancer Research, Pancreas Cancer Research Fund, the Royal College of Surgeons of England, Pharma Nord and Asrazeneca, and grants and personal fees from KAEL Gemvax during the conduct of the study; personal fees from Oxford Biomedica (UK) Ltd, Pfizer, Novartis, Astellas, Abbott (Mylan), Boehringer Ingelheim Pharma and NUCANA. Professor John Neoptolemos is part funded by the NIHR Biomedical Research Centre at the Royal Liverpool University, Liverpool. Professor Paula Ghaneh reports none other than grants from Cancer Research UK and the NIHR. Dr Eithne Costello reports none other than funding by grants from Cancer Research UK, the European Union, Pancreas Cancer UK, North West Cancer Research and Pancreas Cancer Research Fund. Dr William Greenhalf reports none other than funding by grants from Cancer Research UK, the NIHR, the European Union and the Pancreatic Cancer Research Fund. Professor Daniel Palmer reports none other than funding from Cancer Research UK, North West Cancer Research and the NIHR, and personal fees from Bayer-Schering Pharma, Boehringer-Ingelheim, Celgene and Baxter. Dr Victoria Shaw declares no conflict of interest.